Biosimilar bidding in centralized tenders in Norway
Our objective is to study the competition effect of biosimilar entry in centralized tenders for an expensive category or drugs - TNF-inhibitors. We use monthly observations of prices and volumes for all brands and biosimilars in this drug category in Norway, covering the period from Jan. 2006 to De...
Main Authors: | Dag Morten Dalen, Steinar Strøm, Marilena Locatelli |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Oslo
2021-01-01
|
Series: | Nordic Journal of Health Economics |
Subjects: | |
Online Access: | https://journals.uio.no/NJHE/article/view/7394 |
Similar Items
-
Expected Impact of Biosimilars on the Pharmaceutical Companies
by: Shiva Golshani, et al.
Published: (2021-09-01) -
Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
by: Soo-Kyung Park, et al.
Published: (2019-12-01) -
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01) -
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01) -
Revisión de dosieres de heparina y enoxaparina: incumplimiento de la normativa de Costa Rica para el registro sanitario de biosimilares farmacéuticos
by: Rebeca Álvarez Brenes, et al.